Explore our materials

2nd Conference on Innovations in Tuberculosis 2025

Recent Developments in TB Testing and Screening Technologies, Including for HIV-associated TB and TB in Children - Grant Theron - Slideset

2nd Conference on Innovations in Tuberculosis 2025

Recent Developments in TB Testing and Screening Technologies, Including for HIV-associated TB and TB in Children - Grant Theron

(Abstract) #23 Association Between Reservoir Size and Markers of Cardiovascular Inflammation in Perinatally Infected Children Living with HIV

(Abstract) #22 Causes of Death among Sub-Saharan African Infants Living with HIV and Hospitalised with Severe Pneumonia Using Minimally Invasive Autopsies in the EMPIRICAL Trial

(Abstract) #21 Switching Off Dolutegravir in Pregnancy During the Safety Signal Period: A Multi-Cohort European Study

(Abstract) #20 Telomere Length and Neurodevelopmental Outcomes among Children Exposed and Not Exposed to HIV in Kenya

(Abstract) #19 Growth Trajectories Before and After Switching to Dolutegravir in Children Living with HIV in the ODYSSEY Trial

(Abstract) #18 Infectious Morbidity among Children HIV-Exposed, Uninfected in South Africa: Elevated Risk in Infancy But Not Thereafter

(Abstract) #17 Effect of TB Preventive Treatment on TB Incidence and Non-TB-Related Mortality among Children and Adolescents Living with HIV Initiated on Antiretroviral Therapy in Cameroon, 2020-2022

(Abstract) #16 Silent Threats and Missed Opportunities: Rethinking Pediatric TB/HIV Co-Infection Diagnosis in the Era of Advanced HIV Treatment and Universal Test-and-Treat

(Abstract) #15 Efficacy of Second-Line Dolutegravir- versus Boosted Protease Inhibitor-Based ART in Children and Adolescents Living with HIV at 96 and 144 Weeks: Pooled Analysis of the ODYSSEY and CHAPAS-4 Trials

(Abstract) #14 Effectiveness and Safety of Dolutegravir (DTG) in Infants and Children Aged Under 12-Years at Start of DTG in Europe and Thailand